Latest News

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE® (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia (CLL). The ASCEND trial compared CALQUENCE with the investigator’s choice of rituximab combined with idelalisib (IdR) or b

Source link

Related posts

Eko DUO Stethoscope with ECG Built-In Now Available for Purchase


The Origins of Trypillia Megasites


Stanley Black & Decker Getting Into Healthcare: CES 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy